Compounds screening Nuwacell Biotechnologies Co., Ltd. has carried out compounds screening on a variety of primary tissues and human iPSC-derived functional cells. For example, we have carried out more than 3,000 small molecule compounds libraries screening on human epidermal keratinocytes.
Step 1: Introduce a specific compound into the culture of keratinocytes.
Step 2: To identify the different usage of candidate compounds based on their effects on the keratinocytes at their phenotypes of morphology and molecular expression. For example, compounds that can regulate skin cell aging and apoptosis, which can be applied for skin cancer and other malignancies. Otherwise, compounds that can regulate the proliferation and differentiation of skin cells, which can be used to the treatment of skin diseases such as moss and thin stratum corneum. Scale bar, 10 μm.
The advantage of human iPSC-derived functional cells in compounds screening iPSC can differentiate into a variety of human functional cells, such as neurons, cardiomyocytes, liver cells, kidney cells, etc. Researchers can use these cell lines for high-throughput screening of small molecule compounds libraries. For example, patient derived iPSC can be differentiated into a large number of human functional (pathological) cells, which can be used in the pathogenesis study, compound screening, and drug efficacy and safety evaluation, thus can greatly reduce the experiment costs.
Application of human iPSC-derived functional cells in different stages of new drug development (1) Toxicity screening: Large-scale and high-throughput screening of drugs for liver toxicity, kidney toxicity, cardiotoxicity or neurotoxicity in vitro, preliminary screening of the safety and concentration range of these small molecule compounds.
(2) Effectiveness testing: Screen out candidate drugs and dose ranges that are effective for disease treatment for further research.
(3) Clinical safety evaluation: Replace the safety assessment of the current phase I clinical trial, avoid the drug toxicity to patients in the phase I clinical trial, thus can improve the protection of the rights and interests of subjects.
